13F filer · CIK 1121404
Sanofi
Paris, I0 · filing since Q4 2024 · last filing Nov 5, 2026
Reported value
$629.9M
+$95.8M vs prior
Positions
16
New / sold out
6 / 0
Added / reduced
0 / 1
Turnover
0.0%
buys $137.5M · sells $38.2K
Top-10 weight
92.1%
Biggest buys vs Q2 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | Korsana Biosciences | +1,994,011 | – | +$63.8M |
| New | Electra Therapeutics Inc | +2,461,948 | – | +$27.7M |
| New | Attovia Therapeutics Inc | +1,082,855 | – | +$18.6M |
| New | Latigo Biotherapeutics Inc | +672,778 | – | +$11.2M |
| New | Scribe Therapeutics | +500,000 | – | +$9.2M |
| New | SAB BIOTHERAPEUTICS INC | +2,198,500 | – | +$7.0M |
Biggest sells vs Q2 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | Odyssey Therapeutics Inc. | -1,718 | -0.1% | $-38.2K |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q3 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | MeiraGTx Holdings plcCOM | 12,197,737 | $134.2M | 21.30% |
| 2 | Inhibrx Biosciences, Inc.COM | 1,157,926 | $115.9M | 18.40% |
| 3 | NovavaxCOM NEW | 6,880,481 | $74.4M | 11.81% |
| 4 | Korsana BiosciencesCOM | 1,994,011 | $63.8M | 10.13% |
| 5 | Odyssey Therapeutics Inc.COMMON STOCK | 1,990,200 | $44.2M | 7.02% |
| 6 | AnaptysBioCOM | 821,917 | $41.3M | 6.56% |
| 7 | Agomab Therapeutics NVSPONSORED ADS | 2,783,096 | $30.9M | 4.90% |
| 8 | First Tracks Biotherapeutics Inc.ORD SHS | 821,917 | $29.1M | 4.62% |
| 9 | Electra Therapeutics IncCOM | 2,461,948 | $27.7M | 4.40% |
| 10 | Attovia Therapeutics IncCOM | 1,082,855 | $18.6M | 2.95% |
6 more rows. Subscribe for $29/month to see every row, download the data and use the API.